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Background—Excessive drinkers (ED) and patients with alcoholic liver disease (ALD) are 
several times more susceptible to bacterial and viral infections and have a decrease in antibody 
responses to vaccinations. Follicular helper T (TFH) cells are essential to select B cells in the 
germinal center and to produce antibodies. TFH cells express both a membrane-associated and a 
soluble form of CD40 ligand (sCD40L); in which the latter form is released to circulation upon T 
cell activation. The effect of alcohol on TFH cells has not been studied.
Objectives—The goals of this study are to determine the levels of TFH and T helper 1 (Th1) 
cells in ED and those with alcoholic cirrhosis (AC) when compared to healthy controls and to 
determine the prognostic significance of sCD40L in a cohort of patients with AC.
Methods—Controls, ED, and those with AC were enrolled. Baseline demographic, laboratory 
tests, and peripheral blood mononuclear cells (PBMCs) were isolated and assessed via flow 
cytometry for TFH cells. In vitro study was performed to determine the ability of PBMCs to 
secrete interferon (IFN)-γ upon stimulation. Serum sCD40L were also determined and its 
prognostic significance was tested in a cohort of AC patients.
Results—The levels of circulating TFH (cTFH) cells were significantly lower in peripheral blood 
of subjects with ED and AC compared to controls (P<0.05). IFN-γ secretion from PBMCs upon 
stimulation was also lower in ED and those with cirrhosis. Serum sCD40L was significantly lower 
in ED and AC when compared to that in controls (P<0.0005). Its level was an independent 
predictor of mortality.
Conclusions—Patients with AC had significantly lower level of cTFH and sCD40L. The level 
of sCD40L was an independent predictor of mortality in these patients.
Keywords
Follicular helper T (TFH) cells; Circulating follicular helper T (cTFH) cells; T helper 1 (Th1); 
Soluble form of CD40 ligand (sCD40L); Alcoholic liver disease (ALD); Alcoholic cirrhosis (AC)
1. Introduction
Excessive alcohol use is one of the most significant risk factors for health problems such as 
injuries, violence, liver diseases, and cancer.1 Drinking becomes excessive when it causes or 
elevates the risk for alcohol-related problems or complicates the management of other health 
problems. According to the National Institute on Alcohol Abuse and Alcoholism (NIAAA), 
excessive drinkers (ED) are defined as men who drink more than 4 standard drinks in a day 
(or more than 14 per week) and women who drink more than 3 drinks in a day (or more than 
7 per week).2, 3 Alcoholic liver disease (ALD) develops as a consequence of excessive 
alcohol use. It is a complex disorder and its pathogenesis is a multi-step and multi-factorial 
process that progresses through a series of histopathological changes.4 More than 90% of 
drinkers develop alcoholic steatosis which is reversible upon abstinence.5 However, if 
alcohol use continues, the disease may progress to alcoholic hepatitis, advanced fibrosis, and 
alcoholic cirrhosis (AC) in up to 10%–15% of heavy drinkers.4
Excessive alcohol use is strongly associated with immune dysfunction, which can lead to the 
development of ALD. ED are several times more susceptible to bacterial infections, 
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particularly pneumonia, and viral infections.6 Ethanol is a potent immunosuppressive agent 
affecting both innate and adaptive immune responses. For instance, antibody responses to 
hepatitis B vaccination are decreased in those with excessive alcohol use,7 and vaccine titers 
are decreased even further in patients with ALD.8 Excessive alcohol use decreases the 
vaccine response in macaques.9 However, little is known about how alcohol affects the 
adaptive immune system and the mechanisms of how alcohol suppresses the humoral 
response are not well-studied, especially in human subjects. Alcohol is shown to promote 
apoptosis of splenic B and T cells in animal models,10 and decreased T helper (Th) cells 
have been observed in alcoholic patients.8 Patients with ALD develop auto-antibodies 
against modified liver proteins,11 indicating that with long-term alcohol abuse, there is a 
functional, antibody response but this response is dysregulated.
Follicular helper T (TFH) cells are a CD4+ T cell lineage uniquely found in the germinal 
center reaction of secondary lymphoid organs.12 The specific function of TFH cells is to 
select B cells in the germinal center that produce high-affinity antibodies.12–15 TFH cells 
develop initially in response to antigen presentation by dendritic cells, and require germinal 
center B cells for their complete differentiation.12 TFH cells have an activated, effector T 
cell phenotype and uniquely express high levels of both the chemokine (C-X-C motif) 
receptor 5 (CXCR5) and the inhibitory receptor programmed death 1 (PD-1).12 TFH cells 
have been described for both mouse and human, and they control the initiation as well as the 
outcome of germinal center B cell responses, through CD40 ligand (CD40L).12 On TFH 
cells, CD40L promotes B cell maturation and function by engaging CD40 on the B cell 
surface and stimulating B cell secretion of immunoglobulin.16 TFH cells express both a 
membrane-associated and a soluble form of CD40L (sCD40L); the latter form is released 
into circulation upon T cell activation.17 TFH cells are required to generate long-lived 
antibody responses, which confer long term protection to pathogens following infection. 
Recently, a TFH-like cell population has been identified in the circulation (circulating TFH 
cells, cTFH cells).18–20 In humans, these cTFH cells can be divided into Th1-, Th2- and 
Th17-like subsets.21 CXCR3+cTFH cells are related to Th1 cells, CCR6+cTFH cells are 
related to Th17 cells, and CXCR3−CCR6−cTFH cells are Th2-like.21 Although their origins 
are not well understood, cTFH cells appear to be precursors to TFH cells, and they form 
early in an immune response and disseminate to provide key TFH activity to other parts of 
the body.19 Several studies have shown that the percentage of cTFH cells increases with an 
ongoing antibody response in autoimmunity, vaccination and infection.18–20
To date, no information is available about cTFH cells and its subsets in patients with 
excessive alcohol use or those with ALD. The objectives of this study are to (i) determine 
the levels of CXCR3+ and CXCR3−cTFH cells in subjects with excessive alcohol use and 
those with end stage ALD, AC, when compared to healthy controls and (ii) determine the 
prognostic significance of sCD40L in patients with AC.
2. Materials and methods
2.1. Human subject recruitment
2.1.1. Determine the levels of cTFH cells in subjects with excessive alcohol 
use and those with AC when compared to healthy controls—For these 
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experiments, we recruited 4 healthy controls, 21 ED, and 8 with AC. ED were enrolled from 
Fairbanks Alcohol and Drug Addiction Treatment Center (Indianapolis, USA). All met the 
definition of excessive alcohol use as defined by the National Institutes of Health (NIH)/
NIAAA criteria.2, 3 All reported drinking excessively until the time of enrollment. They 
were at least 21 years old without underlying medical illnesses. These subjects had normal 
hepatic panel and denied past history of jaundice or complications from liver diseases, 
history of chronic viral hepatitis, and history of any infections within 4 weeks prior to 
enrollment. Subjects with AC were enrolled from the hepatology clinic at Indiana University 
(Indianapolis, USA). These patients had history of alcohol consumption averaging at least 
80 g per day (for men) or 50 g per day (for women), for at least 10 years.22 This criterion is 
based on epidemiological evidence of the alcohol consumption and cirrhosis relationship.23 
The diagnosis of cirrhosis was made by radiographic imaging compatible with cirrhosis 
and/or history of ascites, grade 2 or higher hepatic encephalopathy and/or the presence of 
esophageal varices on upper gastrointestinal endoscopy, or biopsy-proven cirrhosis, with 
exclusion of other chronic liver diseases. At the time of enrollment, Child-Pugh 
classification and model for end stage liver disease (MELD) scores were calculated.24 
Decompensated cirrhosis patients were those with Child-Pugh class B or C.
2.1.2. Determine the prognostic significance of sCD40L in a cohort of patients 
with AC—Serum levels of sCD40L were measured in 30 healthy controls, 30 ED, and 83 
patients with AC. Patients with AC were recruited between October 2012 and September 
2013 and prospectively followed until death, liver transplantation, or study closure date of 
December 31, 2015. The study was approved by the Institutional Review Board at the 
Indiana University Purdue University Indianapolis (IUPUI) and Fairbanks Alcohol and Drug 
Addiction Treatment Center, and Roudebush VAMC Research and Development Program. 
Written informed consent was obtained from each participant.
2.2. Peripheral blood mononuclear cells (PBMCs) isolation
PBMCs were isolated from a subset of controls, ED, and those with AC as previously 
described.3 The levels of cTFH cells were determined using flow cytometry. In some 
experiments, the function of PBMCs was assessed by determining their responses to secrete 
interferon (IFN)-γ. Briefly, PBMCs from controls, ED and AC were cultured in buffered 
Roswell Park Memorial Institute (RPMI) 1640 supplemented with 10% (v/v) heat 
inactivated fetal bovine serum (FBS). Triplicate PBMC cultures (105 cells/mL) were treated 
with or without 50 ng/mL phorbol 12-myristate 13-acetate (PMA) plus 1 μg/mL ionomycin 
for 4 hours and the levels of IFN-γ in the supernatant were measured.
2.3. Flow cytometry reagents and cell staining
Anti-human CD3 (clone SP34-2), CD45RA (clone HI500), CD4 (clone RPA-T4), PD-1 
(clone MIH4), CXCR5 (clone MU5UBEE) and CXCR3 (clone IC6) antibodies conjugated 
with appropriate fluorochromes were purchased from eBioscience (San Diego, CA) or BD 
Pharmingen (San Jose, CA). Cells from different conditions were subjected to surface 
staining with antibodies at 4 for 30 min. After washing, cells were stained with Fixable 
Viability Dye eFluor® 780 (Life Technologies) for 5 min in the dark. They were then 
washed, twice with 2% FBS/phosphate buffered solution (PBS), then subjected to flow 
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cytometry analysis (FACS) using the BD LSR II Flow Cytometer or BD LSR Fortessa (San 
Diego, CA). Flow cytometry data were analyzed using FlowJo software (Ashland, Oregon). 
Cell sorting was performed on a BD FACSAria machine.
2.4. Flow cytometric gating strategy
The gating strategy for flow cytometry analysis was as follows: (i) live PBMCs were 
selected for by gating on viability dye negative cells; (ii) gating for CD4+CD3+ cells; (iii) 
resulting cells gated on CD45RA−CD4+ cells; (iv) resulting cells gated on CD4+CXCR5+ 
cells; (iv) resulting cells assessed based on expression of PD-1 and CXCR3.
2.5. Analysis of IFN-γ and sCD40L
Commercially available enzyme-linked immunosorbent assays (ELISAs) were used 
according to the manufacturers’ protocols for measuring IFN-γ (R&D System, Cat#DIF50, 
Minneapolis, MN), and sCD40L (R&D System, Cat#SCDL40, Minneapolis, MN) from the 
supernatant.
2.6. Statistical analysis
The PRISM7 program was used for statistical calculations. Basic descriptive statistics, 
including mean, standard deviations (SD), and frequencies (percentages) were used. One-
way analysis of variance, with Tukey post hoc analysis, was used to compare the mean 
differences for continuous variables among the study cohorts. For prognostic significance of 
sCD40L in patients with AC, we examined the time to mortality using log-rank test. 
Individuals who did not die or underwent liver transplantation were censored. Cox 
regression models were used to determine the independent predictors of mortality. P< 0.05 
was considered statistically significant.
3. Results
3.1. The levels of cTFH cells in ED and subjects with AC
Before analyzing the cTFH cell populations in our patient samples, we first analyzed total 
CD4+ T cells and the fraction of activated or memory CD4+ T cells in the PBMCs samples. 
As shown in Fig. 1A, ED showed almost twice as many total CD4+ T cells on average 
compared to controls; however due to high inter-subject variability, the increase was not 
statistically significant. Patients with AC, however, showed a significant increase in total 
CD4+ T cells, over 2-fold on average, compared to controls.
We next determined the level of activated or memory CD4+T cells by staining for CD45RA 
marker. CD45RA is expressed on naive T cells, as well as the effector CD4+T cells. After 
antigen experience, activated/memory T cells lose the expression of CD45RA (CD45RA−). 
Thus CD45RA can be used to generally differentiate the naive from activated/memory T cell 
populations. Both ED and AC patients showed an average increase in activated/memory 
CD4+T cells; however, neither increase reached statistical significance (Fig. 1B). We then 
analyzed CD4+CD45RA−CXCR5+PD-1+cTFH cells by dividing them into CXCR3+ (Th1-
like) and CXCR3− (non-Th1-like) fractions. When calculated as a fraction of total live cells, 
both ED and AC patients showed a highly significant decrease in CXCR3+ cTFH cells 
Hollister et al. Page 5
Liver Res. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
compared to controls (Fig. 1C). There were no significant differences in CXCR3−cTFH cells 
in ED and AC patients, when compared to controls (Fig. 1D). However, AC patients had 
significantly more of this cell population compared to ED. A similar pattern was seen when 
CXCR3+ and CXCR3− cTFH cells were calculated as a fraction of the activated/memory 
CD4+ T cell population (Fig. 2).
To further analyze the subsets of these T cells population, we next assessed cTFH cells 
compared to non-cTFH cells, stratified by subtypes of surface markers CXCR3+ (Th1) and 
CXCR3− (Th2/Th17) populations (Fig. 3). We observed that both Th1-like cTFH cells and 
Th1 non-cTFH cells were significantly decreased in ED and AC patients, compared to 
controls (Figs. 3A and C). Conversely, levels of non-Th1-like cTFH cells and non-Th1, non-
cTFH cells were not significantly different between patient groups (Figs. 3B and D). A 
similar pattern was observed when levels of each cell type, as a fraction of the CD45RA− 
(activated/memory) population, were analyzed (Fig. 4). Taken together, these data show that 
excessive alcohol consumption significantly decreases Th1 and Th1-like TFH cells 
circulating in the blood; however, no major differences in these cell types were seen between 
ED and AC patients.
3.2. IFN-γ production by the PBMCs from controls, ED and patients with AC
We next determined the function of PBMCs by determining their responses to secrete IFN-γ 
upon stimulation with PMA/ionomycin. Triplicate PBMC cultures (105 cells/mL) from 3 
study cohorts (N=10 in each group) were treated with or without PMA/ionomycin for 4 
hours and the levels of IFN-γ in supernatant were measured (Fig. 5). We found that the level 
of IFN-γ in the supernatant from ED ((209.3±29.3) pg/mL) and AC ((133.0±37.2) pg/mL) 
patients were significantly lower than that of controls ((404.3±4.3) pg/mL, P<0.05).
3.3. Serum levels of sCD40L among controls, ED, and patients with AC
sCD40L is released from the TFH cells upon T cell activation.17 We next determined the 
level of sCD40L in a large cohort of controls (N=30), ED (N=30), and AC (N=83). Baseline 
demographic and clinical data were shown in Table 1. The serum level of sCD40L was 
significantly lower in ED( (511±302 )pg/mL) and AC( (452±142 )pg/mL) when compared to 
that of controls( (915±579 )pg/mL, P<0.0005) (Fig. 6A). Among patients with AC, sCD40L 
levels were significantly lower in subjects with decompensated state (Child-Pugh B/C, 
(336±72) pg/mL) compared to those in Child-Pugh A ((502±135) pg/mL, P<0.05) (Fig. 6B).
3.4. Serum levels of sCD40L as an independent predictor of mortality in patients with AC
To determine the prognostic significance of sCD40L, we prospectively followed patients 
with AC with the follow up of 3.2 years. During the follow up period, 15 (18%) patients 
died. In the multivariate Cox model adjusting for age, the level of sCD40L (hazard ratio 
(HR) 0.98, 95% confidence interval (CI) 0.97–0.98, P=0.001) and MELD scores (HR 1.14, 
95% CI 1.016–1.221, P=0.02) were the independent predictors of mortality. The baseline 
sCD40L and MELD scores on the survival of patients with AC is shown in Figs. 6 C and D.
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4. Discussion
The major findings of this study provide some mechanistic insights on why ED and those 
with AC have an increasing risk of bacterial and viral infections.6 We found that (i) 
excessive alcohol consumption significantly decreased Th1 and Th1-like TFH cells 
circulating in the blood, (ii) the function of PBMCs to secrete IFN-γ upon stimulation was 
impaired in ED and patients with AC, (iii) ED and subjects with AC had lower serum level 
of sCD40L, and (iv) the serum level of sCD40L was an independent predictor of mortality in 
patients with AC.
Previous studies have shown that excessive alcohol use leads to the increase in the levels of 
endotoxin (or lipopolysaccharides, LPS), the main driver in the pathogenesis of alcohol-
induced liver injury in rodent models of acute or chronic alcohol consumption as well as in 
humans.25, 26 Once in the circulation, LPS can activate immune cells such as monocytes; 
resulting in the release of inflammatory cascades.27 Our work provides the additional 
understanding on the effect of excessive alcohol use on a specific subtype of T cells, called 
TFH cells. TFH cells are specialized providers of T cell help to B cells, and are essential for 
germinal center formation, affinity maturation, and the development of most high affinity 
antibodies and memory B cells.12–15, 28 TFH cells play an important role for the generation 
of most isotype switched and affinity matured antibodies, and therefore they have an obvious 
function in protective immunity against pathogens.28 Despite the well described function of 
TFH cells in antibody responses, little is known about the effects of alcohol on TFH cells 
especially in humans. We found that excessive alcohol consumption significantly decreased 
circulating Th1 and Th1-like TFH cells when compared to healthy controls. However, no 
differences were observed in these cell populations between ED and AC subjects. The effect 
of alcohol on TFH cells may partly explain the susceptibility to bacterial and viral infection 
among these patients.6 Further, this may underlie the poor antibody responses after 
vaccination among excessive alcohol users and those with ALD.7,8 Not only that alcohol 
interfered with the quantity of circulating Th1 and Th1-like TFH cells, our data also 
indicated that alcohol also impaired the ability of PBMCs to secrete IFN-γ upon stimulation.
sCD40L, an 18-kDa protein, is normally released from T cells upon activation.17 Its level 
has been reported to increase in several disease conditions.29, 30 We found that the serum 
level of sCD40L was lower in ED and those with AC when compared to controls. Whether 
this observation is an indicator of alcohol-induced T cell suppression should be further 
investigated. We observed that the level of sCD40L was the lowest in patients with AC. 
Given that sCD40L can be released from platelets,31 it is possible that the lowest level of 
sCD40L is secondary to the low platelet counts in these patients compared to controls and 
ED (Table 1). Another interesting observation in our study was that the level of sCD40L was 
an independent predictor of mortality in patients with AC. Given the sample size of our 
patients, we should interpret our results with caution. A future study with a larger cohort of 
patients and the comprehensive analyses on the outcomes to see whether lower serum 
sCD40L increasing risk of bacterial/viral infection in patients with AC are needed. Since we 
only studied patients with AC, one form of ALD, detailed analyses on the levels as well as 
function of cTFH in another form of ALD, such as alcoholic hepatitis, is warranted.
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In summary, we found that excessive alcohol consumption significantly decreased 
circulating Th1, Th1-like TFH cells, and serum levels of sCD40L. Future studies are needed 
to further explore the molecular mechanism of these clinical observations and to confirm the 
prognostic significance of sCD40L in patients with AC.
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Fig. 1. Levels of total CD4+T cells, CD4+ memory T cells, CXCR3+ and CXCR3−cTFH cells in 
the study cohorts in relative to frequency of live cells
Th cell proportions in Control, ED and AC patients. Whole PBMCs from patients were 
stained for viability and assessed via flow cytometry. Percentages shown are of live cells. 
Normal control N =4, ED N = 21, AC N =8. (A) Percentage of CD3+ CD4+ T cells in total 
live cells. (B) Percentage of CD3+ CD4+ CD45RA− memory T cells in total live cells. (C) 
Percentage of CD3+ CD4+ CD45RA− CXCR5+ CXCR3+ PD-1+cTFH cells in total live 
cells. (D) Percentage of CD3+ CD4+ CD45RA− CXCR5+ CXCR3− PD-1+cTFH cells in 
total live cells. P-values shown via analysis of variance (ANOVA) with Tukey post-hoc 
analysis. Abbreviation: N.S., not significant.
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Fig. 2. Levels of CXCR3+ and CXCR3−cTFH cells in the study cohorts in relative to frequency of 
activated/memory CD4 T cell population
CXCR3 expression on cTFH cells in Control, ED and AC patients. Whole PBMCs from 
patients were stained for viability, CD3, CD4, and CD45RA and assessed via flow 
cytometry. Percentages shown are gated on live, CD3+ CD4+ CD45RA− cells. Normal 
control N =4, ED N = 21, AC N =8. (A) Percentage of CXCR5+ CXCR3+ PD-1+cTFH cells 
in CD45RA− cells. (B) Percentage of CXCR5+ CXCR3− PD-1+cTFH cells in CD45RA− 
cells. P-values shown via ANOVA with Tukey post-hoc analysis. Abbreviation: N.S., not 
significant.
Hollister et al. Page 11
Liver Res. Author manuscript; available in PMC 2019 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 3. Levels of cTFH and non-TFH cells stratified by subtypes in relative to frequency of live 
cells
CXCR3 expression on cTFH cells, Th1 cells, and memory cells, as percent of total cells, in 
Control, ED and AC patients. Whole PBMCs from patients were stained for viability and 
assessed via flow cytometry. Percentages shown are of live cells. Normal control N =4, ED 
N = 21, AC N =8. (A) Percentage of CD3+ CD4+ CD45RA− CXCR5+ CXCR3+ PD-1+cTFH 
cells in total live cells. (B) Percentage of CD3+ CD4+ CD45RA− CXCR5+ CXCR3− 
PD-1+cTFH cells in total live cells. (C) Percentage of CD3+ CD4+ CD45RA− CXCR5− 
CXCR3+ PD-1+ Th1 cells in total live cells. (D) Percentage of CD3+ CD4+ CD45RA− 
CXCR5− CXCR3− PD-1+ cells in total live cells. P-values shown via ANOVA with Tukey 
post-hoc analysis. Abbreviation: N.S., not significant.
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Fig. 4. Levels of cTFH and non-TFH cells stratified by subtypes in relative to frequency of 
activated/memory CD4 T cell population
CXCR3 expression on cTFH cells, Th1 cells, and memory cells as percent of activated Th 
cells in Control, ED and AC patients. Whole PBMCs from patients were stained for 
viability, CD3, CD4, and CD45RA and assessed via flow cytometry. Percentages shown are 
gated on live, CD3+ CD4+ CD45RA− cells. Normal control N =4, ED N = 21, ALD N =8. 
(A) Percentage of CXCR5+ CXCR3+ PD-1+cTFH cells in CD45RA− cells. (B) Percentage 
of CXCR5+ CXCR3− PD-1+cTFH cells in CD45RA− cells. (C) Percentage of CXCR5− 
CXCR3+ PD-1+ Th1 cells in CD45RA− cells. (D) Percentage of CXCR5− CXCR3− PD-1+ 
cells in CD45RA− cells. P-values shown via ANOVA with Tukey post-hoc analysis. 
Abbreviation: N.S., not significant.
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Fig. 5. IFN-γ production by the PBMCs from controls, ED and patients with AC
PBMCs were isolated from the whole blood of human subjects and plated at the density of 
105 cells/well with or without PMA/ionomycin for 4 hours. The IFN-γ production in the 
supernatant was measured. *P<0.05 compared to controls and respective samples without 
PMA/ionomycin, ^P<0.05 compared to Control with PMA/ionomycin.
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Fig. 6. Serum levels of sCD40L in the study cohorts and survival curve on the baseline of sCD40L 
and MELD scores on survival of patients with AC
(A) Serum levels of sCD40L in the study cohorts. (B) Serum levels of sCD40L in Child A 
vs. Child B/C. (C–D) Survival curve of sCD40L and MELD scores on the survival in 
patients with AC. Abbreviation: MELD, model for end stage liver disease.
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Table 1
Baseline demographic and clinical characteristics of the study cohort.
Variables Healthy Controls (N=30) ED without liver diseases 
(N=30)
AC (N=83)
Age (years) 32.9±9.7 38.2±12.2 50.4±9.2
Men (%) 63 90 77
Race, White (%) 83 83 93
Total drinks in the last 30 days before enrollment 
(standard drinks)
N/A 384.1 ± 185.7 See footnote below*
WBC (cells/mm3) 4.7±1.4 5.5±1.3 8.0±11.4
Hemoglobin (g/dL) 14.3±1.6 13.8±1.4 11.7±2.9
Platelet counts (cells/mm3) 238.6±46.6 233.9±53.4 147.1±74.3
T. Bilirubin (mg/dL) 0.8±0.3 1.0±0.1 2.3±3.6
INR 0.9±0.3 0.9±0.1 1.3±0.5
AST (U/L) 19±4 21±7 37.3±57.9
ALT (U/L) 21±5 20±9 45.7±36.8
Albumin (g/dL) 3.9±0.5 3.8±0.3 3.3±0.6
Creatinine (mg/dL) 0.8±0.3 1.0±0.2 1.1±0.4
Child-Pugh classification(%)
- A 69
- B N/A N/A 20
- C 11
MELD scores N/A N/A 11.2±6.3
*
History of alcohol consumption averaging at least 80 g per day (for men) or 50 g per day (for women), for at least 10 years. Data are expressed as 
mean±SD. Abbreviations: WBC, white blood cell; INR, international normalized ratio; AST, aspartate aminotransferase; ALT, alanine 
aminotransferase; MELD, model for end stage liver disease; N/A, not applicable.
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